Alembic Pharmaceuticals Ltd

Alembic Pharmaceuticals Ltd | Sector: Pharmaceuticals | ISIN: INE901L01018

₹ 496.35 (5.91%) icon

31 Mar, 2023, 3:54:19 PM
Open
₹ 479.40
Prev. Close
₹ 468.65
Turnover(lac)
₹ 5,606.58
Day's High
₹ 509.40
Day's Low
₹ 471.00
52 Wk High
₹ 792.90
52 Wk Low
₹ 462.30
Book Value
₹ 280.14
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 9,756.41
P/E
20.85
EPS
23.79
Div. Yield
2.02

Stock View

info icon
Edit Image

HOLD

Target | 20 Mar, 2023

598.444 (20.57%)

Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is engaged in the active pharmaceutical ingredient (API) business and real estate business. Its pharmace... Read More

KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 3/31/2023 3:54:19 PM

    ₹ 496.35 27.70 5.91
  • Open
  • ₹ 479.4
  • Prev. Close
  • ₹ 468.65
  • Turnover(Lac.)
  • ₹ 5,607
  • Day's High
  • ₹ 509.4
  • Day's Low
  • ₹ 471
  • 52 Week's High
  • ₹ 792.9
  • 52 Week's Low
  • ₹ 462.3
  • Book Value
  • ₹ 280.14
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 9,756.41
  • P/E
  • 20.85
  • EPS
  • 23.79
  • Divi. Yield
  • 2.02

Corporate Actions

02 Mar , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

17 Jan , 2023

12:00 AM

17 Jan , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

19 Sep , 2022

12:00 AM

AGM

Announcement date: 19 Sep , 2022

View Details

31 Oct , 2022

12:00 AM

31 Oct , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 May , 2022

12:00 AM

Dividend

Dividend amount: 10
Announcement date: 02 May , 2022

View Details

20 Jul , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

20 Jul , 2022

12:00 AM

10 May , 2022

12:00 AM

20 Apr , 2022

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

SHAREHOLDING SNAPSHOT
02 April , 2023 | 10:35 AM

PROMOTER - TOTAL69.61%

Indian: 69.10%

Foreign: 0.5123%

NON-PROMOTER - TOTAL 30.39%

Institutions: 17.74%

Non-Institutions: 12.65%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Alembic Pharmaceuticals Ltd News and Update

Article Image
  • 27 March, 2023 |
  • 4:08 PM

The valuation of the company was estimated to be up to $3 billion.

Image not found
  • IIFL News Service |
  • 24 March, 2023 |
  • 4:03 PM
Article Image
ad IconAd Image

FINANCIALS

PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Alembic Pharmaceuticals Ltd

  • Chirayu R Amin

  • Chairman & CEO
  • Pranav N Parikh

  • Independent Director
  • K G Ramanathan

  • Independent Director
  • Paresh Saraiya

  • Independent Director
  • Rajkumar Baheti

  • Director (Finance) & CFO
  • Pranav Amin

  • Managing Director
  • Shaunak Amin

  • Managing Director
  • Archana Hingorani

  • Independent Director
  • Charandeep Singh Saluja

  • Company Secretary
  • Ashok Barat

  • Independent Director

Summary

Alembic Pharmaceuticals manufactures and markets generic pharmaceutical products all over the world. The companys state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. The company is one of the leaders in branded generics in India. Alembic Pharmaceuticals Ltd was incorporated on June 16, 2010 as a wholly owned subsidiary of Alembic Ltd. The company is engaged in pharmaceuticals business. As per the scheme of arrangement, the Pharmaceutical Undertaking of the Alembic Ltd was demerged and transferred to the company with effect from appointed date, April 1, 2010. In April 15, 2011, the company ceased to be a subsidiary of Alembic Ltd consequent to the allotment of 13,35,15,914 equity shares of Rs 2 each to the shareholders of Alembic Ltd as per the scheme of arrangement. The shareholding of Alembic Ltd in the company reduced from 100% to 29.18%. Thus, the company became an associate of Alembic Ltd.In September 20, 2011, the equity shares of the company were listed on the Bombay Stock Exchange and National Stock Exchange. During 2012, Alembic and Breckenridge Announced Paragraph IV ANDA Litigation with Pfizer on Desvenlafaxine (Pristiq). The company enters into a product development and license agreement with Accu-Break Pharmaceuticals, Inc, USA. During 2013, the company got USFDA approval for its NDA - Desvenlafaxine Base Extended Release Tablets and also entered into an out-licensing... Read More


Reports by Alembic Pharmaceuticals Ltd


Reports by Alembic Pharmaceuticals Ltd